TNFR2: Role in Cancer Immunology and Immunotherapy
Yang Yang,Yuanjia Hu,Xin Chen,Md Sahidul Islam
DOI: https://doi.org/10.2147/ITT.S255224
2022-05-25
ImmunoTargets and Therapy
Abstract:Yang Yang, Md Sahidul Islam, Yuanjia Hu, Xin Chen State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, SAR, 999078, People's Republic of China Correspondence: Xin Chen State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Avenida da Universidade, Taipa, Macau, SAR, 999078, People's Republic of China Tel +853 8822 4513 Fax +853 2884 1358 Email Immune checkpoint inhibitors (ICIs), including anti-CTLA-4 (cytotoxic T lymphocyte antigen-4) and anti-PD-1/PD-L1 (programmed death-1/programmed death-ligand 1), represent a turning point in the cancer immunotherapy. However, only a minor fraction of patients could derive benefit from such therapy. Therefore, new strategies targeting additional immune regulatory mechanisms are urgently needed. CD4 + Foxp3 + regulatory T cells (Tregs) represent a major cellular mechanism in cancer immune evasion. There is compelling evidence that tumor necrosis factor (TNF) receptor type II (TNFR2) plays a decisive role in the activation and expansion of Tregs and other types of immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs). Furthermore, TNFR2 is also expressed by some tumor cells. Emerging experimental evidence indicates that TNFR2 may be a therapeutic target to enhance naturally occurring or immunotherapeutic-triggered anti-tumor immune responses. In this article, we discuss recent advances in the understanding of the mechanistic basis underlying the Treg-boosting effect of TNFR2. The role of TNFR2-expressing highly suppressive Tregs in tumor immune evasion and their possible contribution to the non-responsiveness to checkpoint treatment are analyzed. Moreover, the role of TNFR2 expression on tumor cells and the impact of TNFR2 signaling on other types of cells that shape the immunological landscape in the tumor microenvironment, such as MDSCs, MSCs, ECs, EPCs, CD8 + CTLs, and NK cells, are also discussed. The reports revealing the effect of TNFR2-targeting pharmacological agents in the experimental cancer immunotherapy are summarized. We also discuss the potential opportunities and challenges for TNFR2-targeting immunotherapy. Keywords: TNF, TNFR2, cancer immunology and immunotherapy, CD4 + Foxp3 + regulatory T cells, tumor immune microenvironment Cancer immunotherapy, broadly defined as a treatment that can enhance anti-cancer immune responses by targeting certain immune cells or molecules, has achieved significant advances in the past decades and currently becomes a mainstream therapy in cancer treatment, alongside surgery, chemotherapy, and radiotherapy. 1 The successful clinical trials of immune checkpoint inhibitors (ICIs), with blockade antibodies such as ipilimumab and nivolumab/pembrolizumab against CTLA-4 or PD-1 respectively, have transformed the ICIs into major therapy in the advanced non-small cell lung cancer (NSCLC) and melanoma (FDA-approved ICIs are summarized in Table 1). 2,3 However, only a minor fraction of patients can obtain a complete response after such treatment. 4 Moreover, by stimulating the activation of immune cells, treatment with ICIs could result in inflammatory side effects known as immune-related adverse events (irAEs). 5 Treatment with these agents could also upregulate the expression of additional immune checkpoint molecules and consequently induce resistance to immunotherapy. 6 Table 1 FDA-Approved Immune Checkpoint Inhibitors (ICIs) for Cancer Treatment The fact that TNF expression is elevated in the tumor environment and this cytokine can be further enhanced by immunotherapy has recently spurred the extensive discussion about the exact role of TNF in cancer immunology and cancer immunotherapy. 7–10 TNF levels are increased in patients with irAEs, raising the possibility that TNF may play a major role in the inflammatory side effect of ICIs. 11 Indeed, it was reported that the treatment with anti-TNF antibody is effective in the control of irAEs in patients. 12 TNF is an extremely pleiotropic cytokine and its biological functions are mediated by one of its two surface receptors, TNFR1 (TNF receptor type I) and TNFR2. Unlike TNFR1, TNFR2 has no death domain, and its activation can lead to the activation of NF-κB (Nuclear Factor Kappa B) and cell growth. 13–16 TNFR1 is ubiquitously expressed, while the expression of TNFR2 is limited to a certain type of cells, including activated T lymphocytes especially CD4 + Foxp3 + Tregs, endothelial cells, and neural cells. 17–21 Our previous study indicated that TNF-TNFR2 interaction plays a decisive role in the activation, expansion, function -Abstract Truncated-